Literature DB >> 33694070

A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough.

Joel Lexchin1,2,3, Adriane Fugh-Berman4.   

Abstract

Gifts from pharmaceutical and medical device companies to physicians in the United States have been reported since 2014, through the Physician Payments Sunshine Act. Although researchers have utilized these data to publish many studies on conflicts of interest (COIs) and prescribing behavior, there is no evidence that physician behavior regarding COI has changed, or that employers, meeting organizers, or medical journals are excluding physicians based on conflicts of interest. Disclosure is necessary but not sufficient to address the damage that industry relationships causes to medical knowledge and public health.
© 2021. Society of General Internal Medicine.

Entities:  

Mesh:

Year:  2021        PMID: 33694070      PMCID: PMC8481515          DOI: 10.1007/s11606-021-06657-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  38 in total

1.  The Effects of Public Disclosure of Industry Payments to Physicians on Patient Trust: A Randomized Experiment.

Authors:  Alison R Hwong; Sunita Sah; Lisa Soleymani Lehmann
Journal:  J Gen Intern Med       Date:  2017-07-17       Impact factor: 5.128

2.  Do ethical Guidelines make a difference to decision-making?

Authors:  M Osborn; R Day; P Komesaroff; A Mant
Journal:  Intern Med J       Date:  2009-03-23       Impact factor: 2.048

3.  Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.

Authors:  Deborah C Marshall; Beverly Moy; Madeleine E Jackson; Tim K Mackey; Jona A Hattangadi-Gluth
Journal:  J Natl Cancer Inst       Date:  2016-07-07       Impact factor: 13.506

4.  Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.

Authors:  Colette DeJong; Thomas Aguilar; Chien-Wen Tseng; Grace A Lin; W John Boscardin; R Adams Dudley
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

5.  Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors.

Authors:  Waqas Haque; Maria Alvarenga; David Hsiehchen
Journal:  Oncologist       Date:  2020-04-20

Review 6.  Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.

Authors:  Quinn Grundy; Roojin Habibi; Adrienne Shnier; Christopher Mayes; Wendy Lipworth
Journal:  Health Policy       Date:  2018-03-21       Impact factor: 2.980

7.  Association of Mandatory Disclosure Policies and Laws With Physician-Industry Financial Relationships.

Authors:  Alyssa A Horstman; Leslie M Niziol; Susan Chimonas; Paul R Lichter
Journal:  JAMA Ophthalmol       Date:  2019-05-01       Impact factor: 7.389

8.  Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis.

Authors:  Marissa King; Connor Essick; Peter Bearman; Joseph S Ross
Journal:  BMJ       Date:  2013-01-30

9.  Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.

Authors:  Manvi Sharma; Aisha Vadhariya; Michael L Johnson; Zachary A Marcum; Holly M Holmes
Journal:  BMC Health Serv Res       Date:  2018-04-02       Impact factor: 2.655

10.  Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.

Authors:  Alice Fabbri; Ancel la Santos; Signe Mezinska; Shai Mulinari; Barbara Mintzes
Journal:  Int J Health Policy Manag       Date:  2018-06-01
View more
  7 in total

1.  COVID-19 Vaccine Task Force and Conflicts of Interest.

Authors:  Joel Lexchin
Journal:  Healthc Policy       Date:  2022-02

2.  Health Services and Policy Research in Canada: An Editor's Reflections.

Authors:  Joel Lexchin
Journal:  Healthc Policy       Date:  2022-02

3.  Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines.

Authors:  Andrea E Bombak; Louise Adams; Patricia Thille
Journal:  Can J Public Health       Date:  2022-07-15

4.  Physicians' attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey.

Authors:  Marlene Stoll; Lara Hubenschmid; Cora Koch; Klaus Lieb; Boris Egloff
Journal:  BMJ Open       Date:  2022-06-24       Impact factor: 3.006

Review 5.  Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.

Authors:  Piotr Ozieranski; Luc Martinon; Pierre-Alain Jachiet; Shai Mulinari
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

6.  Pharmaceutical Sales Representatives in the United States and China: The Need for Professional Public Space.

Authors:  Xiaoying Chen
Journal:  Health Care Anal       Date:  2021-11-11

7.  Drug company payments to General Practices in England: Cross-sectional and social network analysis.

Authors:  Eszter Saghy; Shai Mulinari; Piotr Ozieranski
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.